-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is the most common cancer in U.Smen except skin cancerAccording to the American Cancer Society, about 175,000 new prostate cancer patients are diagnosed each year in the United States, and more than 315,000 men die from prostate cancer:Emmett L, Crumbaker M, Nguyen A, et al ,(mCRPC)。 Trials of targeted radionuclide therapy 177Lu PSMA 617 have been shown to be safe and effective in some men; Based on these trials, the researchers paired 177Lu PSMA 617 with the tumor-specific radiation sensitization agent idronoxil (NOX66) to assess the response of patients with severe mCRPCPhase I/II trials included 16 progressive mCRPC patients who had previously been treatedAll men received 6 doses of 177Lu PSMA 617 every 6 weeksHalf of patients (queue 1) received 400mg of additional treatment per day for 10 daysFollowing the safety data review, the remaining patients (queue 2) received 800 mg of additional treatment per day for NOX66The researchers found that nearly 70 percent of patients had reduced PSA levels by more than 50 percent after joint treatment (62.5 percent in group 1 and 75 percent in group 2)In addition, 31% of patients reported side effects such as fatigue and pneumonia (37.5% in queue 1 and 12.5% in queue 2)"Preliminary results from the dose upgrade study at this stage show that the combination is targeted and well tolerated, with no increase in toxicity of 177Lu PSMA 617, and is effective for male patients who have received various treatments." Dr Louise Emmett, associate professor at the University of New South Wales in Sydney, saidshe continued: "We are now in the second phase of the dose expansion experiment to further assess toxicity and efficacyThis provides a very important possibility for co-therapeutic effects of joint tumor-targeted therapy drugs without increasing side effects"
Reference: New combination therapy sage as safe and an effective for prostate cancer